Audit of budesonide/formoterol prescribing for asthma in community pharmacy in the U.K

Anne C Boyter, Naomi H Ford, Leon Zlotos

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The rapid action of the long acting beta agonist formoterol allows it to be used as both a preventer and reliever in the management of asthma. The Symbicort® SMART dosing regime has been shown to reduce the number of asthma exacerbations. The aim was to determine the current prescribing of Symbicort®, the prescribing of the SMART regimen and the co-prescribing of a short acting beta agonist with this regimen by means of an audit of prescriptions dispensed in a pharmacy multiple in the U.K. Anonymised data were collected on a standard form. Symbicort® prescribing data for six months were extracted from the pharmacy Patient Medication Record (PMR). Data were stratified by age and analysed to determine adherence with Symbicort® SMART prescribing as defined by the U.K. product license. Data were received from 51 of the 118 (43.2%) pharmacies contacted. Complete information from 2484 PMRs was included in the study. 2.81% (70/2484) of patients were prescribed SMART as defined by the U.K. summary of product characteristics. Of the 18-35 year age group 7.44% (27/363) were prescribed SMART correctly. However, Symbicort® was prescribed twice a day and when required, with either the co-prescription of a SABA, or at an unlicensed dose in 2.46% (61/2484) and 0.28% (7/2484) patients respectively. The incidence of Symbicort® SMART prescribing in this study is low but may be underestimated due to unclear dosing instructions.
LanguageEnglish
Pages864-868
Number of pages5
JournalRespiratory Medicine
Volume105
Issue number6
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Budesonide
Pharmacies
Asthma
Prescriptions
Licensure
Formoterol Fumarate Drug Combination Budesonide
Formoterol Fumarate
Age Groups
Incidence

Keywords

  • adolescent
  • adrenal cortex hormones
  • adult
  • aged
  • asthma
  • budesonide
  • child
  • cost-benefit analysis
  • drug combinations
  • drug therapy combination
  • ethanolamines
  • female
  • Great Britain
  • humans
  • male
  • medical audit
  • middle aged
  • pharmacies
  • young adult

Cite this

@article{8ac055ceb89b4ee3b98214a76b182bf5,
title = "Audit of budesonide/formoterol prescribing for asthma in community pharmacy in the U.K",
abstract = "The rapid action of the long acting beta agonist formoterol allows it to be used as both a preventer and reliever in the management of asthma. The Symbicort{\circledR} SMART dosing regime has been shown to reduce the number of asthma exacerbations. The aim was to determine the current prescribing of Symbicort{\circledR}, the prescribing of the SMART regimen and the co-prescribing of a short acting beta agonist with this regimen by means of an audit of prescriptions dispensed in a pharmacy multiple in the U.K. Anonymised data were collected on a standard form. Symbicort{\circledR} prescribing data for six months were extracted from the pharmacy Patient Medication Record (PMR). Data were stratified by age and analysed to determine adherence with Symbicort{\circledR} SMART prescribing as defined by the U.K. product license. Data were received from 51 of the 118 (43.2{\%}) pharmacies contacted. Complete information from 2484 PMRs was included in the study. 2.81{\%} (70/2484) of patients were prescribed SMART as defined by the U.K. summary of product characteristics. Of the 18-35 year age group 7.44{\%} (27/363) were prescribed SMART correctly. However, Symbicort{\circledR} was prescribed twice a day and when required, with either the co-prescription of a SABA, or at an unlicensed dose in 2.46{\%} (61/2484) and 0.28{\%} (7/2484) patients respectively. The incidence of Symbicort{\circledR} SMART prescribing in this study is low but may be underestimated due to unclear dosing instructions.",
keywords = "adolescent, adrenal cortex hormones, adult, aged, asthma, budesonide, child, cost-benefit analysis, drug combinations, drug therapy combination, ethanolamines, female, Great Britain, humans, male, medical audit, middle aged, pharmacies, young adult",
author = "Boyter, {Anne C} and Ford, {Naomi H} and Leon Zlotos",
note = "Copyright {\circledC} 2010 Elsevier Ltd. All rights reserved.",
year = "2011",
month = "6",
doi = "10.1016/j.rmed.2010.11.021",
language = "English",
volume = "105",
pages = "864--868",
journal = "Respiratory Medicine",
issn = "0954-6111",
number = "6",

}

Audit of budesonide/formoterol prescribing for asthma in community pharmacy in the U.K. / Boyter, Anne C; Ford, Naomi H; Zlotos, Leon.

In: Respiratory Medicine, Vol. 105, No. 6, 06.2011, p. 864-868.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Audit of budesonide/formoterol prescribing for asthma in community pharmacy in the U.K

AU - Boyter, Anne C

AU - Ford, Naomi H

AU - Zlotos, Leon

N1 - Copyright © 2010 Elsevier Ltd. All rights reserved.

PY - 2011/6

Y1 - 2011/6

N2 - The rapid action of the long acting beta agonist formoterol allows it to be used as both a preventer and reliever in the management of asthma. The Symbicort® SMART dosing regime has been shown to reduce the number of asthma exacerbations. The aim was to determine the current prescribing of Symbicort®, the prescribing of the SMART regimen and the co-prescribing of a short acting beta agonist with this regimen by means of an audit of prescriptions dispensed in a pharmacy multiple in the U.K. Anonymised data were collected on a standard form. Symbicort® prescribing data for six months were extracted from the pharmacy Patient Medication Record (PMR). Data were stratified by age and analysed to determine adherence with Symbicort® SMART prescribing as defined by the U.K. product license. Data were received from 51 of the 118 (43.2%) pharmacies contacted. Complete information from 2484 PMRs was included in the study. 2.81% (70/2484) of patients were prescribed SMART as defined by the U.K. summary of product characteristics. Of the 18-35 year age group 7.44% (27/363) were prescribed SMART correctly. However, Symbicort® was prescribed twice a day and when required, with either the co-prescription of a SABA, or at an unlicensed dose in 2.46% (61/2484) and 0.28% (7/2484) patients respectively. The incidence of Symbicort® SMART prescribing in this study is low but may be underestimated due to unclear dosing instructions.

AB - The rapid action of the long acting beta agonist formoterol allows it to be used as both a preventer and reliever in the management of asthma. The Symbicort® SMART dosing regime has been shown to reduce the number of asthma exacerbations. The aim was to determine the current prescribing of Symbicort®, the prescribing of the SMART regimen and the co-prescribing of a short acting beta agonist with this regimen by means of an audit of prescriptions dispensed in a pharmacy multiple in the U.K. Anonymised data were collected on a standard form. Symbicort® prescribing data for six months were extracted from the pharmacy Patient Medication Record (PMR). Data were stratified by age and analysed to determine adherence with Symbicort® SMART prescribing as defined by the U.K. product license. Data were received from 51 of the 118 (43.2%) pharmacies contacted. Complete information from 2484 PMRs was included in the study. 2.81% (70/2484) of patients were prescribed SMART as defined by the U.K. summary of product characteristics. Of the 18-35 year age group 7.44% (27/363) were prescribed SMART correctly. However, Symbicort® was prescribed twice a day and when required, with either the co-prescription of a SABA, or at an unlicensed dose in 2.46% (61/2484) and 0.28% (7/2484) patients respectively. The incidence of Symbicort® SMART prescribing in this study is low but may be underestimated due to unclear dosing instructions.

KW - adolescent

KW - adrenal cortex hormones

KW - adult

KW - aged

KW - asthma

KW - budesonide

KW - child

KW - cost-benefit analysis

KW - drug combinations

KW - drug therapy combination

KW - ethanolamines

KW - female

KW - Great Britain

KW - humans

KW - male

KW - medical audit

KW - middle aged

KW - pharmacies

KW - young adult

UR - http://www.scopus.com/inward/record.url?scp=79955480693&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2010.11.021

DO - 10.1016/j.rmed.2010.11.021

M3 - Article

VL - 105

SP - 864

EP - 868

JO - Respiratory Medicine

T2 - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 6

ER -